Opiant Pharmaceuticals Inc (NASDAQ:OPNT) Short Interest Down 29.5% in August
Opiant Pharmaceuticals Inc (NASDAQ:OPNT) was the recipient of a large decline in short interest during the month of August. As of August 31st, there was short interest totalling 10,500 shares, a decline of 29.5% from the August 15th total of 14,900 shares. Approximately 0.3% of the company’s stock are short sold. Based on an average daily trading volume, of 45,800 shares, the short-interest ratio is presently 0.2 days.
A number of institutional investors and hedge funds have recently bought and sold shares of OPNT. Fondren Management LP increased its stake in shares of Opiant Pharmaceuticals by 18.6% in the first quarter. Fondren Management LP now owns 314,300 shares of the technology company’s stock worth $3,011,000 after acquiring an additional 49,400 shares during the period. Stonepine Capital Management LLC raised its stake in shares of Opiant Pharmaceuticals by 14.0% during the 1st quarter. Stonepine Capital Management LLC now owns 380,948 shares of the technology company’s stock valued at $3,649,000 after buying an additional 46,676 shares during the last quarter. Alambic Investment Management L.P. acquired a new position in shares of Opiant Pharmaceuticals in the 1st quarter valued at about $147,000. Acadian Asset Management LLC boosted its stake in shares of Opiant Pharmaceuticals by 439.7% in the first quarter. Acadian Asset Management LLC now owns 8,128 shares of the technology company’s stock worth $79,000 after buying an additional 6,622 shares during the last quarter. Finally, Advisor Group Holdings Inc. acquired a new stake in Opiant Pharmaceuticals during the first quarter worth about $45,000. 19.32% of the stock is owned by institutional investors.
Separately, ValuEngine raised shares of Opiant Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 2nd.
Opiant Pharmaceuticals (NASDAQ:OPNT) last released its earnings results on Thursday, August 6th. The technology company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.26. Opiant Pharmaceuticals had a net margin of 25.32% and a negative return on equity of 2.43%. The company had revenue of $6.31 million for the quarter, compared to the consensus estimate of $6.47 million. On average, research analysts forecast that Opiant Pharmaceuticals will post -0.83 earnings per share for the current fiscal year.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
Featured Story: Benefits of owning preferred stock
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.